Details for Patent: 10,258,622

« Back to Dashboard

Which drugs does patent 10,258,622 protect, and when does it expire?

Patent 10,258,622 protects BRAFTOVI and is included in one NDA.

This patent has forty-eight patent family members in thirty-nine countries.

Summary for Patent: 10,258,622

Title:	Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
Abstract:	This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methyl-sulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.
Inventor(s):	Daya Verma, Yogita Krishnamachari, Xiaohong Shen, Hanchen Lee, Ping Li, Rajinder Singh, LayChoo Tan
Assignee:	Array Biopharma Inc
Application Number:	US15/452,239
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,258,622
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form;

Drugs Protected by US Patent 10,258,622

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes	10,258,622					BRAFTOVI, IN COMBINATION WITH CETUXIMAB AND FLUOROURACIL- BASED CHEMOTHERAPY, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-AUTHORIZED TEST, AS CLAIMED
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes	10,258,622					BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes	10,258,622					BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB AND MFOLFOX6, FOR THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST

International Family Members for US Patent 10,258,622

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	088936
Australia	2012340759
Brazil	112014011981
Canada	2856406
Chile	2014001337
China	103945831
China	105708819